Review

Role of histone acetylation in gastric cancer: implications of dietetic compounds and clinical perspectives

*Author for correspondence: Tel.: +55 91 3201 6776;

Programa de Pós-graduação em Oncologia e Ciências Médicas, Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, Brazil

Programa de Pós-graduação em Química Medicinal e Modelagem Molecular, Universidade Federal do Pará, Belém, PA, Brazil

Residência Multiprofissional em Saúde/Oncologia, Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém, PA, Brazil

^‡Authors contributed equally

Search for more papers by this author

Fernanda Wisnieski^‡

Disciplina de Genética, Universidade Federal de São Paulo, SP, Brazil

^‡Authors contributed equally

Search for more papers by this author

Elizangela R da Silva Mota

Programa de Pós-graduação em Química Medicinal e Modelagem Molecular, Universidade Federal do Pará, Belém, PA, Brazil

Search for more papers by this author

Stefanie B Maia de Sousa

Programa de Pós-graduação em Oncologia e Ciências Médicas, Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, Brazil

Search for more papers by this author

Jéssica M Costa da Silva

Faculdade de Biotecnologia, Universidade Federal do Pará, Belém, PA, Brazil

Search for more papers by this author

Mariana F Leal

Programa de Pós-graduação em Oncologia e Ciências Médicas, Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, Brazil

Disciplina de Genética, Universidade Federal de São Paulo, SP, Brazil

Search for more papers by this author

Carolina O Gigek

Disciplina de Genética, Universidade Federal de São Paulo, SP, Brazil

Departamento de Patologia, Universidade Federal de São Paulo, SP, Brazil

Search for more papers by this author

Leonardo C Santos

Disciplina de Genética, Universidade Federal de São Paulo, SP, Brazil

Search for more papers by this author

Lucas T Rasmussen

Disciplina de Genética, Universidade Federal de São Paulo, SP, Brazil

Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade do Sagrado Coração, Bauru, SP, Brazil

Search for more papers by this author

Paulo P Assumpção

Programa de Pós-graduação em Oncologia e Ciências Médicas, Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, Brazil

Search for more papers by this author

Rommel R Burbano

Programa de Pós-graduação em Oncologia e Ciências Médicas, Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, Brazil

Laboratório de Biologia Molecular, Hospital Ophir Loyola, Belém, PA, Brazil

Search for more papers by this author

Marília AC Smith

Disciplina de Genética, Universidade Federal de São Paulo, SP, Brazil

Search for more papers by this author

Published Online:23 Jan 2019https://doi.org/10.2217/epi-2018-0081

Abstract

Histone modifications regulate the structural status of chromatin and thereby influence the transcriptional status of genes. These processes are controlled by the recruitment of different enzymes to a specific genomic site. Furthermore, obtaining an understanding of these mechanisms could help delineate alternative treatment and preventive strategies for cancer. For example, in gastric cancer, cholecalciferol, curcumin, resveratrol, quercetin, garcinol and sodium butyrate are natural regulators of acetylation and deacetylation enzyme activity that exert chemopreventive and anticancer effects. Here, we review the recent findings on histone acetylation in gastric cancer and discuss the effects of nutrients and bioactive compounds on histone acetylation and their potential role in the prevention and treatment of this type of cancer.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1 Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359–E386 (2015).Crossref, Medline, CAS, Google Scholar
2 Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: progression in early diagnosis and prognosis (review). Oncol. Lett. 9(4), 1502–1508 (2015).Crossref, Medline, CAS, Google Scholar
3 Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J. Surg. Oncol. 107(3), 230–236 (2013).Crossref, Medline, Google Scholar
4 Riquelme I, Saavedra K, Espinoza JA et al. Molecular classification of gastric cancer: towards a pathway-driven targeted therapy. Oncotarget 6(28), 24750–24779 (2015).Crossref, Medline, Google Scholar
5 Cristescu R, Lee J, Nebozhyn M et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21(5), 449–456 (2015).Crossref, Medline, CAS, Google Scholar
6 Wang K, Yuen ST, Xu J et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet. 46(6), 573–582 (2014).Crossref, Medline, CAS, Google Scholar
7 Cui J, Yin Y, Ma Q et al. Comprehensive characterization of the genomic alterations in human gastric cancer. Int. J. Cancer 137(1), 86–95 (2015).Crossref, Medline, CAS, Google Scholar
8 Gigek CO, Calcagno DQ, Rasmussen LT et al. Genetic variants in gastric cancer: risks and clinical implications. Exp. Mol. Pathol. 103(1), 101–111 (2017).Crossref, Medline, CAS, Google Scholar
9 Deans C, Maggert KA. What do you mean, ‘epigenetic’? Genetics 199(4), 887–896 (2015).Crossref, Medline, CAS, Google Scholar
10 Gigek CO, Chen ES, Calcagno DQ, Wisnieski F, Burbano RR, Smith MA. Epigenetic mechanisms in gastric cancer. Epigenomics 4(3), 279–294 (2012). • Reports a large number of epigenetic mechanisms in gastric cancer and their clinical implications, including DNA methylation, histone modifications and microRNA expression.Link, CAS, Google Scholar
11 Calcagno DQ, Gigek CO, Chen ES, Burbano RR, Smith M de A. DNA and histone methylation in gastric carcinogenesis. World J. Gastroenterol. 19(8), 1182–1192 (2013).Crossref, Medline, CAS, Google Scholar
12 Calcagno DQ, Smith MAC, Burbano RR. Cancer type-specific epigenetic changes: gastric cancer. In: Cancer Epigenetics. Risk Assessment, Diagnosis, Treatment and Prognosis. Verma ME (Ed.). Humana Press, NY, USA, 79–101 (2015).Crossref, Google Scholar
13 Audia JE, Campbell RM. Histone modifications and cancer. Cold Spring Harb Perspect. Biol. 8(4), a019521 (2016).Crossref, Medline, Google Scholar
14 Calcagno DQ, Oliveira KCS, Martins NNF. Nutritional and epigenetics implicationsin esophageal cancer. In: Handbook of Nutrition, Diet, and Epigenetics. Preedy VR, Patel VB (Eds). Springer International Publishing, NY, USA, 1–19 (2017).Google Scholar
15 Gigek CO, Chen ES, Smith MAC. Epigenetic alterations in stomach cancer: implications for diet and nutrition. In: Handbook of Nutrition, Diet, and Epigenetics. Preedy VR, Patel VB (Eds). Springer International Publishing, NY, USA, 1–18 (2017).Crossref, Google Scholar
16 Legube G, Trouche D. Regulating histone acetyltransferases and deacetylases. EMBO Rep. 4(10), 944–947 (2003). • Describes the regulation of histone acetylation and how these events influence cellular responses to environmental changes.Crossref, Medline, CAS, Google Scholar
17 Wapenaar H, Dekker FJ. Histone acetyltransferases: challenges in targeting bi-substrate enzymes. Clin. Epigenetics 8, 59 (2016).Crossref, Medline, Google Scholar
18 Di Cerbo V, Schneider R. Cancers with wrong HATs: the impact of acetylation. Brief. Funct. Genomics 12(3), 231–243 (2013).Crossref, Medline, CAS, Google Scholar
19 Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect. Biol. 6(4), a018713 (2014).Crossref, Medline, Google Scholar
20 Shanmugam MK, Arfuso F, Arumugam S et al. Correction: role of novel histone modifications in cancer. Oncotarget 9(27), 19460 (2018).Crossref, Medline, Google Scholar
21 Wisnieski F, Calcagno DQ, Leal MF et al. Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A. Tumour Biol. 35(7), 6373–6381 (2014).Crossref, Medline, CAS, Google Scholar
22 Sakuraba K, Yokomizo K, Shirahata A et al. TIP60 as a potential marker for the malignancy of gastric cancer. Anticancer Res. 31(1), 77–79 (2011).Medline, CAS, Google Scholar
23 Iizuka M, Takahashi Y, Mizzen CA et al. Histone acetyltransferase Hbo1: catalytic activity, cellular abundance, and links to primary cancers. Gene 436(1-2), 108–114 (2009).Crossref, Medline, CAS, Google Scholar
24 Zhu L, Yang J, Zhao L et al. Expression of hMOF, but not HDAC4, is responsible for the global histone H4K16 acetylation in gastric carcinoma. Int. J. Oncol. 46(6), 2535–2545 (2015).Crossref, Medline, CAS, Google Scholar
25 Cao L, Zhu L, Yang J et al. Correlation of low expression of hMOF with clinicopathological features of colorectal carcinoma, gastric cancer and renal cell carcinoma. Int. J. Oncol. 44(4), 1207–1214 (2014).Crossref, Medline, CAS, Google Scholar
26 Koshiishi N, Chong JM, Fukasawa T et al. p300 gene alterations in intestinal and diffuse types of gastric carcinoma. Gastric Cancer 7(2), 85–90 (2004).Crossref, Medline, Google Scholar
27 Ying MZ, Wang JJ, Li DW et al. The p300/CBP associated factor is frequently downregulated in intestinal-type gastric carcinoma and constitutes a biomarker for clinical outcome. Cancer Biol. Ther. 9(4), 312–320 (2010).Crossref, Medline, CAS, Google Scholar
28 Kim MS, Lee SH, Yoo NJ. Frameshift mutations of tumor suppressor gene EP300 in gastric and colorectal cancers with high microsatellite instability. Hum. Pathol. 44(10), 2064–2070 (2013).Crossref, Medline, CAS, Google Scholar
29 Choi JH, Kwon HJ, Yoon BI et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J. Cancer Res. 92(12), 1300–1304 (2001).Crossref, Medline, CAS, Google Scholar
30 Mutze K, Langer R, Becker K et al. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Ann. Surg. Oncol. 17(12), 3336–3343 (2010).Crossref, Medline, Google Scholar
31 Sudo T, Mimori K, Nishida N et al. Histone deacetylase 1 expression in gastric cancer. Oncol. Rep. 26(4), 777–782 (2011).Medline, CAS, Google Scholar
32 Gao F, Lv Y, Zhu Y et al. Correlation of epigenetic aberrance with STAT3 signaling pathway in gastric carcinogenesis. Dig. Dis. Sci. 57(8), 2055–2062 (2012).Crossref, Medline, CAS, Google Scholar
33 Cao LL, Yue Z, Liu L et al. The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy. Oncotarget 8(24), 39241–39253 (2017).Crossref, Medline, Google Scholar
34 Feng AN, Zhang LH, Fan XS et al. Expression of SIRT1 in gastric cardiac cancer and its clinicopathologic significance. Int. J. Surg. Pathol. 19(6), 743–750 (2011).Crossref, Medline, CAS, Google Scholar
35 He Q, Li G, Wang X et al. A decrease of histone deacetylase 6 expression caused by Helicobacter pylori infection is associated with oncogenic transformation in gastric cancer. Cell Physiol. Biochem. 42(4), 1326–1335 (2017).Crossref, Medline, CAS, Google Scholar
36 Song J, Noh JH, Lee JH et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113(4), 264–268 (2005).Crossref, Medline, CAS, Google Scholar
37 Weichert W, Roske A, Gekeler V et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 9(2), 139–148 (2008).Crossref, Medline, CAS, Google Scholar
38 Yu Y, Cao F, Yu X et al. The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis. Clin. Transl. Oncol. 19(8), 1045–1054 (2017).Crossref, Medline, CAS, Google Scholar
39 Kang Y, Jung WY, Lee H, Lee E, Kim A, Kim BH. Expression of SIRT1 and DBC1 in gastric adenocarcinoma. Korean J. Pathol. 46(6), 523–531 (2012).Crossref, Medline, Google Scholar
40 Wu S, Jiang J, Liu J, Wang X, Gan Y, Tang Y. Meta-analysis of SIRT1 expression as a prognostic marker for overall survival in gastrointestinal cancer. Oncotarget 8(37), 62589–62599 (2017).Crossref, Medline, Google Scholar
41 Yang Q, Wang B, Gao W et al. SIRT1 is downregulated in gastric cancer and leads to G1-phase arrest via NF-kappaB/Cyclin D1 signaling. Mol. Cancer Res. 11(12), 1497–1507 (2013).Crossref, Medline, CAS, Google Scholar
42 Zhang S, Huang S, Deng C et al. Co-ordinated overexpression of SIRT1 and STAT3 is associated with poor survival outcome in gastric cancer patients. Oncotarget 8(12), 18848–18860 (2017).Crossref, Medline, Google Scholar
43 Shen X, Li P, Xu Y et al. Association of sirtuins with clinicopathological parameters and overall survival in gastric cancer. Oncotarget 8(43), 74359–74370 (2017).Crossref, Medline, Google Scholar
44 Peters CJ, Rees JR, Hardwick RH et al. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 139(6), 1995–2004; e1915 (2010).Crossref, Medline, CAS, Google Scholar
45 Huang G, Cui F, Yu F et al. Sirtuin-4 (SIRT4) is downregulated and associated with some clinicopathological features in gastric adenocarcinoma. Biomed. Pharmacother. 72, 135–139 (2015).Crossref, Medline, CAS, Google Scholar
46 Zhang S, Chen P, Huang Z et al. Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a. Sci. Rep. 5, 9787 (2015).Crossref, Medline, CAS, Google Scholar
47 Calcagno DQ, Freitas VM, Leal MF et al. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer. BMC Gastroenterol. 13, 141 (2013).Crossref, Medline, Google Scholar
48 De Souza CR, Leal MF, Calcagno DQ et al. MYC deregulation in gastric cancer and its clinicopathological implications. PLoS ONE 8(5), e64420 (2013).Crossref, Medline, Google Scholar
49 Mitani Y, Oue N, Hamai Y et al. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma. J. Pathol. 205(1), 65–73 (2005).Crossref, Medline, CAS, Google Scholar
50 Wisnieski F, Calcagno DQ, Leal MF et al. CDKN1A histone acetylation and gene expression relationship in gastric adenocarcinomas. Clin. Exp. Med. 17(1), 121–129 (2017).Crossref, Medline, CAS, Google Scholar
51 Angrisano T, Lembo F, Peluso S, Keller S, Chiariotti L, Pero R. Helicobacter pylori regulates iNOS promoter by histone modifications in human gastric epithelial cells. Med. Microbiol. Immunol. 201(3), 249–257 (2012).Crossref, Medline, CAS, Google Scholar
52 Ding SZ, Fischer W, Kaparakis-Liaskos M et al. Helicobacter pylori-induced histone modification, associated gene expression in gastric epithelial cells, and its implication in pathogenesis. PLoS ONE 5(4), e9875 (2010).Crossref, Medline, Google Scholar
53 Liu C, Xu D. Inhibition of histone deacetylases. In: Epigenetics Protocols. Methods in Molecular Biology. Tollefsbol TO (Ed.). Humana Press, NJ, USA, 87–97 (2011).Google Scholar
54 Liu C, Pan Y, Wang X, Lu J, Huang B, Li X. Activation of RASSF2A by p300 induces late apoptosis through histone hyperacetylation. Cell Biol. Int. 34(12), 1133–1139 (2010).Crossref, Medline, CAS, Google Scholar
55 Wang XH, Zhang LH, Zhong XY et al. S100A6 overexpression is associated with poor prognosis and is epigenetically upregulated in gastric cancer. Am. J. Pathol. 177(2), 586–597 (2010).Crossref, Medline, CAS, Google Scholar
56 Song IS, Ha GH, Kim JM et al. Human ZNF312b oncogene is regulated by Sp1 binding to its promoter region through DNA demethylation and histone acetylation in gastric cancer. Int. J. Cancer 129(9), 2124–2133 (2011).Crossref, Medline, CAS, Google Scholar
57 Qinyu L, Long C, Zhen-Dong D et al. FOXO6 promotes gastric cancer cell tumorigenicity via upregulation of C-myc. FEBS Lett. 587(14), 2105–2111 (2013).Crossref, Medline, Google Scholar
58 Lee SH, Kim J, Kim WH, Lee YM. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. Oncogene 28(2), 184–194 (2009).Crossref, Medline, CAS, Google Scholar
59 Ma J, Wang JD, Zhang WJ et al. Promoter hypermethylation and histone hypoacetylation contribute to pancreatic-duodenal homeobox 1 silencing in gastric cancer. Carcinogenesis 31(9), 1552–1560 (2010).Crossref, Medline, CAS, Google Scholar
60 Yun J, Song SH, Park J et al. Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers. Lab. Invest. 92(7), 1033–1044 (2012).Crossref, Medline, CAS, Google Scholar
61 Zhu XJ, Liu J, Xu XY, Zhang CD, Dai DQ. Novel tumor-suppressor gene epidermal growth factor-containing fibulin-like extracellular matrix protein 1 is epigenetically silenced and associated with invasion and metastasis in human gastric cancer. Mol. Med. Rep. 9(6), 2283–2292 (2014).Crossref, Medline, CAS, Google Scholar
62 Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int. J. Mol. Sci. 18(7), 114–139 (2017).Crossref, Google Scholar
63 Wu ZQ, Zhang R, Chao C, Zhang JF, Zhang YQ. Histone deacetylase inhibitor trichostatin A induced caspase-independent apoptosis in human gastric cancer cell. Chin. Med. J. 120(23), 2112–2118 (2007).Crossref, Medline, CAS, Google Scholar
64 Zou XM, Li YL, Wang H et al. Gastric cancer cell lines induced by trichostatin A. World J. Gastroenterol. 14(30), 4810–4815 (2008).Crossref, Medline, CAS, Google Scholar
65 Wisnieski F, Leal MF, Calcagno DQ et al. BMP8B is a tumor suppressor gene regulated by histone acetylation in gastric cancer. J. Cell Biochem. 118(4), 869–877 (2017).Crossref, Medline, CAS, Google Scholar
66 Qin HT, Li HQ, Liu F. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives. Expert Opin. Ther. Pat. 27(5), 621–636 (2017).Crossref, Medline, CAS, Google Scholar
67 Iannitti T, Palmieri B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R. D. 11(3), 227–249 (2011).Crossref, Medline, Google Scholar
68 Shi X, Zheng C, Li C et al. 4-Phenybutyric acid promotes gastric cancer cell migration via histone deacetylase inhibition-mediated HER3/HER4 upregulation. Cell Biol. Int. 42(1), 53–62 (2018).Crossref, Medline, CAS, Google Scholar
69 Assumpcao CB, Calcagno DQ, Araujo TM et al. The role of piRNA and its potential clinical implications in cancer. Epigenomics 7(6), 975–984 (2015).Link, CAS, Google Scholar
70 Saito Y, Suzuki H, Taya T et al. Development of a novel microRNA promoter microarray for ChIP-on-chip assay to identify epigenetically regulated microRNAs. Biochem. Biophys. Res. Commun. 426(1), 33–37 (2012).Crossref, Medline, CAS, Google Scholar
71 Braicu C, Mehterov N, Vladimirov B et al. Nutrigenomics in cancer: revisiting the effects of natural compounds. Semin. Cancer Biol. 46, 84–106 (2017). • Summarizes nutrigenomics aspects relevant to cancer, highlighting natural compounds preventive and therapeutic role.Crossref, Medline, CAS, Google Scholar
72 Pan L, Matloob AF, Du J et al. Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A/sodium butyrate-induced and 5-aza-2′-deoxycytidine-induced PTEN upregulation. FEBS J. 277(4), 989–999 (2010).Crossref, Medline, CAS, Google Scholar
73 Hosoda K, Shimomura H, Wanibuchi K et al. Identification and characterization of a vitamin D(3) decomposition product bactericidal against Helicobacter pylori. Sci. Rep. 5, 8860 (2015).Crossref, Medline, Google Scholar
74 Rath S, Das L, Kokate SB et al. Inhibition of histone/lysine acetyltransferase activity kills CoCl2-treated and hypoxia-exposed gastric cancer cells and reduces their invasiveness. Int. J. Biochem. Cell Biol. 82, 28–40 (2017).Crossref, Medline, CAS, Google Scholar
75 Huang F, Yao Y, Wu J et al. Curcumin inhibits gastric cancer-derived mesenchymal stem cells mediated angiogenesis by regulating NF-kappaB/VEGF signaling. Am. J. Transl. Res. 9(12), 5538–5547 (2017).Medline, CAS, Google Scholar
76 De R, Kundu P, Swarnakar S et al. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob. Agents Chemother. 53(4), 1592–1597 (2009).Crossref, Medline, CAS, Google Scholar
77 Yang Q, Wang B, Zang W et al. Resveratrol inhibits the growth of gastric cancer by inducing G1 phase arrest and senescence in a Sirt1-dependent manner. PLoS ONE 8(11), e70627 (2013). • Suggests that resveratrol inhibits gastric cancer in a Sirt1-dependent manner and its potential utility in gastric cancer prevention and therapy.Crossref, Medline, Google Scholar
78 Zhang X, Jiang A, Qi B et al. Resveratrol protects against Helicobacter pylori-associated gastritis by combating oxidative stress. Int. J. Mol. Sci. 16(11), 27757–27769 (2015).Crossref, Medline, CAS, Google Scholar
79 Sekiguchi H, Washida K, Murakami A. Suppressive effects of selected food phytochemicals on CD74 expression in NCI-N87 gastric carcinoma cells. J. Clin. Biochem. Nutr. 43(2), 109–117 (2008).Crossref, Medline, CAS, Google Scholar
80 Lei CS, Hou YC, Pai MH, Lin MT, Yeh SL. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies. J. Nutr. Biochem. 51, 105–113 (2018).Crossref, Medline, CAS, Google Scholar
81 Tang W, Pan M-H, Sang S, Li S, Ho C-T. Garcinol from Garcinia indica: chemistry and health beneficial effects. In: Tropical and Subtropical Fruits: Flavors, Color, and Health Benefits. Patil BS, Jayaprakasha GK, Roa CO, Mahattanatawee K (Eds). American Chemical Society, Washington DC, USA, 133–145 (2013).Crossref, Google Scholar
82 Biersack B. Effects of Garcinol from Kokum (Garcinia indica) on the prevention and treatment of cancer. In: Critical Dietary Factors in Cancer Chemoprevention. Ullah MF, Ahmad A (Eds). Springer International Publishing, Cham, Switzerland, 253–271 (2016).Crossref, Google Scholar
83 Liao CH, Sang S, Liang YC, Ho CT, Lin JK. Suppression of inducible nitric oxide synthase and cyclooxygenase-2 in downregulating nuclear factor-kappa B pathway by Garcinol. Mol. Carcinog. 41(3), 140–149 (2004).Crossref, Medline, CAS, Google Scholar
84 Shin H, Lee YS, Lee YC. Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer cells. Oncol. Rep. 27(4), 1111–1115 (2012).Crossref, Medline, CAS, Google Scholar
85 Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat. Rev. Cancer 14(5), 342–357 (2014).Crossref, Medline, CAS, Google Scholar
86 Fleet JC, Desmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem. J. 441(1), 61–76 (2012).Crossref, Medline, CAS, Google Scholar
87 Abu El Maaty MA, Wolfl S. Effects of 1,25(OH)(2)D(3) on cancer cells and potential applications in combination with established and putative anti-cancer agents. Nutrients 9(1), 87–99 (2017).Crossref, Google Scholar
88 Vyas N, Companioni RC, Tiba M et al. Association between serum vitamin D levels and gastric cancer: a retrospective chart analysis. World J. Gastrointest. Oncol. 8(9), 688–694 (2016).Crossref, Medline, Google Scholar
89 Stefanska B, Karlic H, Varga F, Fabianowska-Majewska K, Haslberger A. Epigenetic mechanisms in anti-cancer actions of bioactive food components: the implications in cancer prevention. Br. J. Pharmacol. 167(2), 279–297 (2012).Crossref, Medline, CAS, Google Scholar
90 Reuter S, Gupta SC, Park B, Goel A, Aggarwal BB. Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr. 6(2), 93–108 (2011).Crossref, Medline, CAS, Google Scholar
91 Vahid F, Zand H, Nosrat-Mirshekarlou E, Najafi R, Hekmatdoost A. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review. Gene 562(1), 8–15 (2015). • Overview of the dietary bioactive compounds role in the regulation of histone acetylases and deacetylases and their health benefits, including genistein, phenylisothiocyanate, curcumin, resveratrol, indole-3-carbinol and epigallocatechin-3-gallate.Crossref, Medline, CAS, Google Scholar
92 Chung S, Yao H, Caito S, Hwang JW, Arunachalam G, Rahman I. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch. Biochem. Biophys. 501(1), 79–90 (2010).Crossref, Medline, CAS, Google Scholar
93 Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell. 16(1), 93–105 (2004).Crossref, Medline, CAS, Google Scholar
94 Qiu G, Li X, Che X et al. SIRT1 is a regulator of autophagy: implications in gastric cancer progression and treatment. FEBS Lett. 589(16), 2034–2042 (2015).Crossref, Medline, CAS, Google Scholar
95 Priyadarsini RV, Vinothini G, Murugan RS, Manikandan P, Nagini S. The flavonoid quercetin modulates the hallmark capabilities of hamster buccal pouch tumors. Nutr. Cancer 63(2), 218–226 (2011).Crossref, Medline, CAS, Google Scholar
96 Ruiz PA, Braune A, Holzlwimmer G, Quintanilla-Fend L, Haller D. Quercetin inhibits TNF-induced NF-kappaB transcription factor recruitment to proinflammatory gene promoters in murine intestinal epithelial cells. J. Nutr. 137(5), 1208–1215 (2007).Crossref, Medline, CAS, Google Scholar
97 Zhang S, Huang J, Xie X, He Y, Mo F, Luo Z. Quercetin from polygonum capitatum protects against gastric inflammation and apoptosis associated with Helicobacter pylori infection by affecting the levels of p38MAPK, BCL-2 and BAX. Molecules 22(5), 744–761 (2017).Crossref, Google Scholar
98 Furdas SD, Kannan S, Sippl W, Jung M. Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates. Arch. Pharm. (Weinheim) 345(1), 7–21 (2012).Crossref, Medline, CAS, Google Scholar
99 Balasubramanyam K, Altaf M, Varier RA et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 279(32), 33716–33726 (2004).Crossref, Medline, CAS, Google Scholar
100 Arif M, Pradhan SK, Thanuja GR et al. Mechanism of p300 specific histone acetyltransferase inhibition by small molecules. J. Med. Chem. 52(2), 267–277 (2009).Crossref, Medline, CAS, Google Scholar
101 Pan MH, Chang WL, Lin-Shiau SY, Ho CT, Lin JK. Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells. J. Agric. Food Chem. 49(3), 1464–1474 (2001).Crossref, Medline, CAS, Google Scholar
102 Liu C, Ho PC, Wong FC, Sethi G, Wang LZ, Goh BC. Garcinol: current status of its anti-oxidative, anti-inflammatory and anti-cancer effects. Cancer Lett. 362(1), 8–14 (2015).Crossref, Medline, CAS, Google Scholar
103 Davie JR. Inhibition of histone deacetylase activity by butyrate. J. Nutr. 133(7 Suppl), 2485S–2493S (2003).Crossref, Medline, CAS, Google Scholar
104 Shin H, Kim JH, Song Y, Yong L, Lee C. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: Induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.. Int. J. Oncol. 1, 1533–1542 (2012).Google Scholar
105 Hernandez-Rosas F, Hernandez-Oliveras A, Flores-Peredo L et al. Histone deacetylase inhibitors induce the expression of tumor suppressor genes Per1 and Per2 in human gastric cancer cells. Oncol. Lett. 16(2), 1981–1990 (2018).Medline, Google Scholar
106 Busch C, Burkard M, Leischner C, Lauer UM, Frank J, Venturelli S. Epigenetic activities of flavonoids in the prevention and treatment of cancer. Clin. Epigenetics 7, 64 (2015).Crossref, Medline, Google Scholar

- Cited By
  - H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy
    22 May 2019 | Cells, Vol. 8, No. 5
Vol. 11, No. 3

Metrics
Downloaded 105 times

History

Received 5 June 2018

Accepted 24 September 2018

Published online 23 January 2019

Published in print February 2019

Information
© 2019 Future Medicine Ltd
Keywords
Author contributions
DQ Calcagno, F Wisnieski and MAC Smith participated in the design, orientation of data search, writing and review of the article. ER da Silva Mota, SBM de Souza, JMC da Silva, MF Leal, CO Gigek, LC Santos and LT Rasmussen participated in the writing and review of the article. PP Assumpção and RR Burbano participated in the review of the article.
Financial & competing interests disclosure
This work was supported by funds from the Fundação de Apoio à Pesquisa do Estado de São Paulo (FAPESP; 2016/25562-0 to MC Smith, 2016/19953-6 to F Wisnieski and 2012/14768-5 to MF Leal), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES; 201567/2009-1 to MC Smith and CO Gigek), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; 311342/2017-5 to DQ Calcagno, 310252/2017-2 to PP Assumpção, 305220/2013-6 to RR Burbano and 303871/2014-8 to MC Smith), and Fundação Amazônia Paraense de Amparo à Pesquisa (FAPESPA; 068/2016 to SBMS). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Loading ...